Jean-Michel Petit1,2, David Masson3, Boris Guiu3,4, Fabien Rollot3, Laurence Duvillard3, Benjamin Bouillet3,5, Marie-Claude Brindisi3,5, Perrine Buffier5, Patrick Hillon3,6, Jean-Pierre Cercueil4, Bruno Verges3,5. 1. Centre de Recherche INSERM Unité 866, Université de Bourgogne, CHU du Bocage, BP 77908, 21079, Dijon Cedex, France. jean-michel.petit@chu-dijon.fr. 2. Services de diabétologie et endocrinologie, CHU du Bocage, BP 77908, 21079, Dijon Cedex, France. jean-michel.petit@chu-dijon.fr. 3. Centre de Recherche INSERM Unité 866, Université de Bourgogne, CHU du Bocage, BP 77908, 21079, Dijon Cedex, France. 4. de radiologie, CHU du Bocage, BP 77908, 21079, Dijon Cedex, France. 5. Services de diabétologie et endocrinologie, CHU du Bocage, BP 77908, 21079, Dijon Cedex, France. 6. d'hépatologie, CHU du Bocage, BP 77908, 21079, Dijon Cedex, France.
Abstract
AIMS: It has recently been shown that an allele in the glucokinase regulatory protein (GCKR) gene was associated with increased liver fat content in obese children. In this study, we set out to determine whether GCKR rs1260326 polymorphism was associated with liver fat content in patients with type 2 diabetes. METHODS: Three hundred and eight patients with type 2 diabetes were included in this study. Liver fat content was evaluated using 1H-MR spectroscopy. RESULTS: In our population, carriers of the rs1260326 minor T allele had a higher liver fat content than did carriers of the C allele homozygote (12.4 ± 9.6 vs. 10.3 ± 9.1 %, p = 0.03). The number of patients with steatosis was significantly higher in minor T allele carriers than in C allele homozygote carriers (70.7 vs. 55.4 %; p = 0.008). In multivariate analysis, the predictive variables for steatosis were BMI [odds ratio (OR) 1.08; 95 % confidence interval (CI) 1.03-1.13; p = 0.002], statin therapy (yes) [OR 0.54; 95 % CI 0.31-0.94; p = 0.03], metformin therapy (yes) [OR 2.67; 95 % CI 1.50-4.75; p < 0.001], and rs1260326 GCKR polymorphism (TT+CT) [OR 1.99; 95 % CI 1.14-3.47; p = 0.01]. CONCLUSIONS: This study shows that in patients with type 2 diabetes who were not selected for liver abnormalities, liver fat content was related to GCKR rs1260326 polymorphism independent of BMI, triglyceride levels, and age.
AIMS: It has recently been shown that an allele in the glucokinase regulatory protein (GCKR) gene was associated with increased liver fat content in obesechildren. In this study, we set out to determine whether GCKRrs1260326 polymorphism was associated with liver fat content in patients with type 2 diabetes. METHODS: Three hundred and eight patients with type 2 diabetes were included in this study. Liver fat content was evaluated using 1H-MR spectroscopy. RESULTS: In our population, carriers of the rs1260326 minor T allele had a higher liver fat content than did carriers of the C allele homozygote (12.4 ± 9.6 vs. 10.3 ± 9.1 %, p = 0.03). The number of patients with steatosis was significantly higher in minor T allele carriers than in C allele homozygote carriers (70.7 vs. 55.4 %; p = 0.008). In multivariate analysis, the predictive variables for steatosis were BMI [odds ratio (OR) 1.08; 95 % confidence interval (CI) 1.03-1.13; p = 0.002], statin therapy (yes) [OR 0.54; 95 % CI 0.31-0.94; p = 0.03], metformin therapy (yes) [OR 2.67; 95 % CI 1.50-4.75; p < 0.001], and rs1260326GCKR polymorphism (TT+CT) [OR 1.99; 95 % CI 1.14-3.47; p = 0.01]. CONCLUSIONS: This study shows that in patients with type 2 diabetes who were not selected for liver abnormalities, liver fat content was related to GCKRrs1260326 polymorphism independent of BMI, triglyceride levels, and age.
Authors: Glen James; Sulev Reisberg; Kaido Lepik; Nicholas Galwey; Paul Avillach; Liis Kolberg; Reedik Mägi; Tõnu Esko; Myriam Alexander; Dawn Waterworth; A Katrina Loomis; Jaak Vilo Journal: PLoS One Date: 2019-04-12 Impact factor: 3.240